Rapid desensitization for non-immediate reactions in patients with cystic fibrosis  by Whitaker, P. et al.
www.elsevier.
Journal of Cystic Fibrosis 10 (2011) 282–285
www.elsevier.com/locate/jcfShort Communication
Rapid desensitization for non-immediate reactions in patients with
cystic fibrosis☆
P. Whitaker a,⁎, N. Shaw a, J. Gooi b, C. Etherington a, S. Conway a, D. Peckham a
a Regional Adult Cystic Fibrosis Unit, St James's Hospital, Leeds, LS9 7TF, United Kingdom
b Department of Immunology, St James's Hospital, Leeds, LS9 7TF, United Kingdom
Received 25 November 2010; received in revised form 13 January 2011; accepted 4 February 2011
Available online 9 March 2011Abstract
Non-immediate hypersensitivity reactions to antibiotics in patients with CF represent a real-life challenge for clinicians. Desensitization is often
performed in patients who have exhausted all therapeutic options. Whilst desensitization is an established procedure for immediate reactions we
assessed the outcomes and safety of desensitization for non-immediate reactions.
We retrospectively reviewed 275 desensitization procedures in 42 patients with a range of non-immediate reactions to six commonly used
antibiotics. Desensitization was performed using a 7-step rapid intravenous protocol on a normal medical ward.
250 (91%) of overall desensitization procedures were successful; however, this figure incorporates certain individuals having multiple
successful procedures. Individual patient success ranged from 55% with tazocin through to 88% with tobramycin. In the 25 patients who failed
desensitization the reactions were mild and the majority occurred within 48 h of starting treatment. Prophylactic anti-histamines and steroids did
not reduce the risk of reaction.
Whilst the mechanisms remain uncertain we can confirm that rapid desensitization is a safe and effective way of re-introducing an antibiotic to
a patient with a non-immediate reaction.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypersensitivity reactions to antimicrobials represent a real-
life challenge in the management of patients with cystic fibrosis
(CF). Studies report that up to 20% of adult patients have had
multiple reactions to beta-lactam antibiotics [1–3]. Reactions
are usually non-immediate and consist of uncomplicated rashes,
arthralgia, and fevers. In the first instance the advice is to avoid
the offending drug. However, whilst alternative regimens can be
devised formost patients there are some for whom all options have
been exhausted. In this difficult group of patients desensitization
represents the safest method of reintroducing the drug to the
patient.☆ Declaration of funding sources: There were no external sources of funding
for this work.
⁎ Corresponding author. Tel.: +44 1132065702.
E-mail addresses: paul.whitaker@leedsth.nhs.uk,
drpaulwhitaker@hotmail.com (P. Whitaker).
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doi:10.1016/j.jcf.2011.02.002Drug desensitization results in a temporary state of immune
tolerance to the offending drug by gradual increasing a suboptimal
dose prior to the full therapeutic dose. It is an established procedure
in patients with CF and immediate antibiotic reactions [4,5]. Most
recently Legere et al. reported 52 successful desensitization
procedures in 15 patients with immediate reactions [5]. Previously
Turvey et al. reported 57 desensitization procedures in 21 patients
with CF and reactions suggestive of IgE mediated immediate
reactions [4].
Non-immediate reactions by definition occur after more than
one hour and are T cell mediated [6]. There is very limited
information available in theCF literature to support desensitization
in non-immediate reactions [7,8]. Burrows et al. included a small
number of patients with non-immediate reactions in their
retrospective study. They did not separate their outcomes from
the patients with immediate reactions [7]. Desensitization to non-
immediate reactions has been successful in other patient groups,
such as with trimethoprim/sulfamethoxazole in patients with
HIV [9].d by Elsevier B.V. All rights reserved.
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of a rapid desensitization protocol in a cohort of patients with cystic
fibrosis and non-immediate reactions to antibiotics.2. Methods
Wereviewed themedical records of all patientswhounderwent
desensitization at the Regional Adult Cystic Fibrosis Unit in St
James's Hospital, Leeds, between 2004 and 2010. Patients were
included when their original reaction developed more than 24 h
after starting the antibiotic and had no features of an IgEmediated
process. This time point was chosen to avoid any overlap with
immediate reactions.
The desensitization procedure follows a standard protocol that
involves a 7-step approach with 10 fold increases in concentration
until the therapeutic dose was achieved. Each step is given over
20 min,with the procedure lasting 2 h and 20 min.Desensitization
was performed on the CF ward with a nurse present at all times.
For the desensitization to be considered successful the patient
needed to complete the full course of treatment. Prophylactic
medication, consisting of either an oral steroid and anti-histamine
or antihistamine alone,was given according to the discretion of the
attending physician.
The study was approved by the Leeds East Ethical Committee.
Statistical analysis of outcomes was performed using the chi-
square test, a p-value less than 0.05 was considered significant.
Table 1
Overall outcomes of desensitization according to each drug. S = steroid and AH =
antihistamine.
Drug Number of
desensitization
procedures
Prophylactic
medication
Completed full
treatment
Success rate
per individual
Tazocin 32 in 11 patients 20 with S
and AH
84% (5 failures) 6/11 (55%)
4 with AH
8 with
no cover
Ceftazidime 83 in 23 patients 28 with S
and AH
90% (8 failures) 15/23 (65%)3. Results
275 desensitization procedures, involving six antibiotics,
were performed in 42 patients. Some patients were desensitized
to more than one drug and the original reactions are shown in
Fig. 1. The frequency of maculopapular reactions was lower in
the tobramycin and colomycin groups when compared to the
beta-lactam antibiotics (p=0.03). For both tobramycin and
colomycin there was a non-significant trend towards a greater
frequency of arthralgia and fever.0
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Fig. 1. Comparison of the types and frequency of original reactions encountered
for each drug. The majority of all reactions were skin reactions, especially
maculopapular and urticarial rashes.250 (91%) of overall desensitization procedures were
successful; however, this figure incorporates many patients who
had repeated successful procedures. Individual patient success
ranged from 55% with tazocin through to 88% with tobramycin.
This data is shown in Table 1.
25 patients failed desensitization and the antibiotic treatment
was stopped (Table 2). In keeping with the original reactions
any reaction occurring following desensitization was also mild
and required no action other than the discontinuation of the
drug. All patients who failed desensitization were successfully
desensitized to an alternative drug. Only two patients failed
more than one desensitization procedure. The first patient failed
with tazocin and aztreonam initially but tolerated meropenem
desensitization. The second patient failed with meropenem and
aztreonam but desensitization was successful with tazocin. No
significant correlation was seen regarding higher risk of failure
and original reaction type.
Prophylactic treatment with steroids and anti-histamine was
given in 108 (39%) of procedures, anti-histamine alone in 54
(20%), and no cover in 113 (41%). There was no significant
difference between outcomes and whether prophylactic medica-
tion was given, also no difference was seen between clinician
decision to start prophylactic medication and the type of original
reaction.10 with AH
45 with
no cover
Meropenem 42 in 13 patients 18 with S
and AH
90% (4 failures) 9/13 (69%)
13 with AH
11 with
no cover
Aztreonam 14 in 10 patients 3 with S
and AH
71% (4 failures) 6/10 (60%)
3 with AH
8 with
no cover
Tobramycin 39 in 8 patients 13 with S
and AH
97% (1 failure) 7/8 (88%)
26 with
no cover
Colomycin 65 in 9 patients 26 with S
and AH
95% (3 failures) 6/9 (67%)
24 with AH
15 with
no cover
Table 2
Individual analysis of each of the failed desensitization procedures. S = oral
steroid and AH = antihistamine.
Drug Original reaction Outcome of
desensitization
Pre-medication
Tazocin Maculopapular rash Maculopapular rash
on day 10
No cover
Tazocin Drug fever Drug fever on day 7 No cover
Tazocin Maculopapular rash Flu-like symptoms on day 1 No cover
Tazocin Maculopapular rash Arthralgia on day 1 S and AH
Tazocin Fixed drug reaction Fixed drug reaction and
pruritis on day 1
S and AH
Ceftazidime Maculopapular rash Maculopapular rash
on day 3
S and AH
Ceftazidime Urticarial rash Fevers and generally
unwell with first full dose
No cover
Ceftazidime Maculopapular rash Swollen lips and
pruritis on day 3
AH
Ceftazidime Maculopapular rash Maculopapular rash
on day 1
AH
Ceftazidime Urticarial rash Urticarial rash and
headache day 1
S and AH
Ceftazidime Urticarial rash Urticarial rash on day 1 No cover
Ceftazidime Urticarial rash Urticarial rash day 1 No cover
Ceftazidime Maculopapular rash Flu-like on day 3 No cover
Meropenem Maculopapular rash Drug fever and generally
unwell on day 2
S and AH
Meropenem Urticarial rash Urticarial rash day 3 S and AH
Meropenem Maculopapular rash Drug fevers and
arthralgia day 2
S and AH
Meropenem Maculopapular rash Generally unwell
during desensitization
No cover
Aztreonam Maculopapular rash Maculopapular rash
on day 3
AH
Aztreonam Pruritis and
arthralgia
Pruritis on day 1 S and AH
Aztreonam Fixed drug reaction Fixed drug reaction 4 h
post desensitization
S and AH
Aztreonam Maculopapular rash Maculopapular rash
on day 2
No cover
Tobramycin Maculopapular rash Unwell and fever
during desensitization
S and AH
Colomycin Urticarial rash Urticarial rash day 4 No cover
Colomycin Urticarial rash Pruritis day 2 AH
Colomycin Angioedema Flu-like symptoms day 1 No cover
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Our clinical experience suggests that desensitization is possible
in patients with CF and non-immediate reactions. Patients were
classified as hypersensitive on clinical grounds alone; this
weakness is in keeping with all previous desensitization series. It
is notoriously difficult to confirm non-immediate hypersensitivity
as both intradermal and patch testing have very low sensitivities
with mild antibiotic reactions [10]. In most cases the only way to
prove the reaction would be give the patient a further course of the
drug intravenously as a form of challenge test, this is generally
considered to be inappropriate when clinical suspicion is high.
Thirty out of the 42 patients (71%) did have negative skin prick
tests performed to the causative drug as part of another study
suggesting a non-IgE mediated process. Twelve patients died
before the skin testing could be performed. The highmortality ratein this group is not surprising as desensitization is most often
performed in patients with multiple allergies and a high burden of
disease.
We did not find any correlation between pre-medication and
outcome. Certainly the effectiveness of steroids and anti-histamines
in T cell mediated reactions is limited and it would not be expected
to alter the course of a reactivated immune system.More aggressive
immunosuppression with agents such as cyclosporin may be more
effective but are unlikely to seen as appropriate in this situation
[11].
The procedures were carried on a routine medical ward with
close nursing observation. Resuscitation facilities and medical
staff were available on the ward in case of complications. The
majority of treatment failures (17/25, 68%) occurred within
48 h of desensitization and it is our practice in Leeds that
patients are observed on the ward for 48 h post-desensitization.
Little is known about the mechanisms of desensitization for
non-immediate reactions. Both regulatory T cells and anti-drug
antibodies have been proposed as mediators to suppress drug
specific T cells. Regulatory T cells are believed to moderate
allergic diseases through inducing immune tolerance [12–14]. It
is possible that during desensitization effector T cell responses
are controlled by these regulatory cells.
A second mechanism may involve hypersensitive patients
mounting a B-cell response and releasing anti-drug antibodies
during desensitization. These have been detected in certain
individuals [15,16] and it has been demonstrated that anti-penicillin
antibody titers rise rapidly during desensitization and then decline
slowly with time [15]. The speed of the response in desensitized
patients would be in keeping with a secondary antibody response.
In conclusion, desensitization is a useful and safe approach in
the management of patients with multiple non-immediate
reactions. It should only be used in mild reactions as reactivation
of severe reactions is a theoretical possibility. A prospective study
with detailed immune surveillance before, during, and after
desensitization is needed to unravel the mechanisms involved.References
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